142 related articles for article (PubMed ID: 14582000)
1. Anemia in the treatment of hepatitis C virus infection.
Sulkowski MS
Clin Infect Dis; 2003; 37 Suppl 4():S315-22. PubMed ID: 14582000
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.
Dieterich DT; Wasserman R; Bräu N; Hassanein TI; Bini EJ; Bowers PJ; Sulkowski MS
Am J Gastroenterol; 2003 Nov; 98(11):2491-9. PubMed ID: 14638354
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
4. Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C.
Sharvadze L; Tsertsvadze T; Gochitashvili N; Kakabadze T; Dolmazashvili E
Georgian Med News; 2006 Aug; (137):62-5. PubMed ID: 16980747
[TBL] [Abstract][Full Text] [Related]
5. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
Pockros PJ; Shiffman ML; Schiff ER; Sulkowski MS; Younossi Z; Dieterich DT; Wright TL; Mody SH; Tang KL; Goon BL; Bowers PJ; Leitz G; Afdhal NH;
Hepatology; 2004 Dec; 40(6):1450-8. PubMed ID: 15565613
[TBL] [Abstract][Full Text] [Related]
6. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
Soriano V; Núñez M; Sánchez-Conde M; Barreiro P; García-Samaniego J; Martín-Carbonero L; Romero M; González-Lahoz J
Antivir Ther; 2005; 10(1):167-70. PubMed ID: 15751774
[TBL] [Abstract][Full Text] [Related]
7. Anemia during treatment of hepatitis C in HIV-infected patients.
Lo Re V; Kostman JR
AIDS Read; 2004 Oct; 14(10):555-7, 562, 565-71. PubMed ID: 15510392
[TBL] [Abstract][Full Text] [Related]
8. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hepatitis C virus infection in thalassemia.
Butensky E; Pakbaz Z; Foote D; Walters MC; Vichinsky EP; Harmatz P
Ann N Y Acad Sci; 2005; 1054():290-9. PubMed ID: 16339677
[TBL] [Abstract][Full Text] [Related]
10. Role of epoetin alfa in maintaining ribavirin dose.
Afdhal NH
Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S25-35. PubMed ID: 15081101
[TBL] [Abstract][Full Text] [Related]
11. Implications of anemia in human immunodeficiency virus, cancer, and hepatitis C virus.
Mildvan D
Clin Infect Dis; 2003; 37 Suppl 4():S293-6. PubMed ID: 14581997
[TBL] [Abstract][Full Text] [Related]
12. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
Sharma P; Marrero JA; Fontana RJ; Greenson JK; Conjeevaram H; Su GL; Askari F; Sullivan P; Lok AS
Liver Transpl; 2007 Aug; 13(8):1100-8. PubMed ID: 17377914
[TBL] [Abstract][Full Text] [Related]
13. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
Alvarez D; Dieterich DT; Brau N; Moorehead L; Ball L; Sulkowski MS
J Viral Hepat; 2006 Oct; 13(10):683-9. PubMed ID: 16970600
[TBL] [Abstract][Full Text] [Related]
14. Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C.
Bräu N
J Viral Hepat; 2004 May; 11(3):191-7. PubMed ID: 15117320
[TBL] [Abstract][Full Text] [Related]
15. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.
De Franceschi L; Fattovich G; Turrini F; Ayi K; Brugnara C; Manzato F; Noventa F; Stanzial AM; Solero P; Corrocher R
Hepatology; 2000 Apr; 31(4):997-1004. PubMed ID: 10733558
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus in human immunodeficiency virus-infected individuals: an emerging comorbidity with significant implications.
Gonzalez SA; Talal AH
Semin Liver Dis; 2003 May; 23(2):149-66. PubMed ID: 12800068
[TBL] [Abstract][Full Text] [Related]
17. Hematologic disorders associated with hepatitis C virus infection and their management.
Dieterich DT; Spivak JL
Clin Infect Dis; 2003 Aug; 37(4):533-41. PubMed ID: 12905138
[TBL] [Abstract][Full Text] [Related]
18. Anemia--a complication of antiviral treatment in chronic viral hepatitis C.
Orāşan O; Cozma A; Rednic N; Sâmpelean D; Pârvu A; Petrov L
Rom J Intern Med; 2009; 47(3):217-25. PubMed ID: 20446436
[TBL] [Abstract][Full Text] [Related]
19. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
Afdhal NH; Dieterich DT; Pockros PJ; Schiff ER; Shiffman ML; Sulkowski MS; Wright T; Younossi Z; Goon BL; Tang KL; Bowers PJ;
Gastroenterology; 2004 May; 126(5):1302-11. PubMed ID: 15131791
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.
Talal AH; Liu RC; Zeremski M; Dimova R; Dove L; Pearce D; Hassanein T; Doonquah L; Aboulafia D; Rodriguez J; Bonilla H; Galpin J; Aberg JA; Johnston B; Glesby MJ; Jacobson IM
J Acquir Immune Defic Syndr; 2011 Nov; 58(3):261-8. PubMed ID: 21876446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
